TRXC AKA TRANSENTERIX will we witness a big full moonSome say Transenterix could be a 16 billion dollar business one day very soon if you see it bounce from the gutter. 900% this year already ill be looking very closely.
It might want to put a stronger foundation by testing the demand zone but after we see a bounce from that or a strong continuation to the upside breaking the pennant we could see a full moon.
notes:
When we look at the MACD we see a little reversal to the downside but this could be to the bottom of the triangle.
Also we see little volume which could indicate on a tight consolidation period maybe? Or that drop to the demand zone.
# I am not a financial advisor, i do this for fun :) Trade at your own risk, remember ALOT of people lose their money.
Transenterix
TRXCKeep a look out for this momentum stock. Over the past month it is up 400%. As I look at the volume on the monthly this stock is surging & showing very bullish signs & short term price activity reflects what buyers have in mind. Can't confirm it is a buy just yet but if we do get a real push up I am eyeing around $20 as a target over the next few months. Which could be a solid 800%.
With FDA approaching, this one is getting ready to bounceHad FDA approval about 6 months ago with another one for 501k submission on the way and technicals look like a breakout is imminent. Watch for support levels at 1.80 and break about 1.93 and 2.02.
TransEnterix Is Attempting To Break Out of a One Year Down TrendTransEnterix is developing the SurgiBot, the first device to directly compete with Intuitive Surgical. In April of 2014, TransEnterix priced their secondary offering on the worst day the Nasdaq had experienced since 2011, which sent their secondary offering price from the $8.00 range to $4.00. In June of 2014 the company was included in the Russell 2000, which resulted in a runup to the $6.00 range. TransEnterix delayed the filing of their SurgiBot device by 6 months in November, which caused the one month sell off to an all time low of $1.50. Now that the company is nearing FDA submission of the SurgiBot, and after several presentations at health care conferences, TRXC is attempting to buck the down trend once and for all. I'm long TRXC, from a fundamental perspective, rather than a technical one. The first fib retracement from April 2014 highs to December 2014 lows is $4.30, then near $6.00
